DALLAS, Jan. 25, 2016 -- Texas Capital Bancshares, Inc. (NASDAQ:TCBI), the parent company of Texas Capital Bank, and their board of directors declared a cash dividend of $0.40625 per share of the non-cumulative perpetual preferred stock, Series A, which is traded on the NASDAQ under the symbol “TCBIP”. The Series A Preferred Stock dividend is payable on March 15, 2016, to shareholders of record at the close of business on March 1, 2016.
ABOUT TEXAS CAPITAL BANCSHARES, INC.
Texas Capital Bancshares, Inc. (NASDAQ:TCBI), a member of the Russell 2000® Index and the S&P SmallCap 600®, is the parent company of Texas Capital Bank, a commercial bank that delivers highly personalized financial services to businesses and entrepreneurs. Headquartered in Dallas, the bank has full-service locations in Austin, Dallas, Fort Worth, Houston and San Antonio.
MEDIA & INVESTOR CONTACT Heather Worley, 214.932.6646 [email protected]


China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



